Cyclin-dependent kinase 8

May 14, 2020

Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Presentation at 25th EHA Congress

Mar 28, 2020

Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia

Nov 05, 2019

Ryvu Therapeutics to Present at BIO-Europe 2019

Sep 06, 2019

Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Sep 03, 2019

Selvita to Present at Upcoming Conferences in September

Jul 25, 2019

Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer

May 22, 2019

Selvita Reports First Quarter 2019 Financial Results and Provides Corporate Update

Mar 26, 2019

Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Mar 21, 2019

Selvita to Host Conference Call and Webcast on Thursday, March 28

Mar 04, 2019

Selvita to Present Data From Multiple Oncology Programs at AACR 2019 Annual Meeting

Jan 02, 2019

Selvita to Present at Biotech Showcase 2019 in San Francisco

Aug 08, 2017

Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 Into Phase I for AML Patients